Key statistics dashboard for Inventiva S.A. (IVA). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Inventiva S.A. is a biopharmaceutical company currently in its clinical development phase, specializing in the creation of orally administered small molecule therapeutics. The firm primarily targets serious conditions such as non-alcoholic steatohepatitis (NASH), various forms of mucopolysaccharidoses (MPS), and other significant diseases.
Stock Data
| Price | $3.79 |
| Market Cap | $197M |
| Enterprise Value | $743.6M |
| Beta | 0.95 |
| Exchange | NASDAQ |
| Country | FR |
Valuation Multiples
| P/E Ratio | -1.74 |
| Price / Book | -74.05 |
| P/S | 174.68 |
| EV/EBITDA | -5.57 |
| EV/Sales | 165.88 |
| EV/FCF | -7.06 |
| P/FCF | -7.43 |
| Earnings Yield | -16.77% |
| FCF Yield | -13.46% |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 35.07% |
| EBIT Margin | -3040.98% |
| EBITDA Margin | -2976.04% |
| Operating Margin | -3037.30% |
| Net Margin | -7899.58% |
| Return on Equity | 1870.38% |
| Return on Assets | -141.93% |
| Return on Invested Capital | -66.18% |
| Return on Capital Employed | -79.10% |
Financial Health
| Current Ratio | 3.16 |
| Quick Ratio | 3.16 |
| Cash Ratio | 1.28 |
| Debt / Equity | -2.10 |
| Debt / Assets | 23.99% |
| Net Debt / EBITDA | 0.30 |
| Interest Coverage | -4.06 |
Per-Share Data
| Revenue per share | 0.01 |
| Book Value per share | -0.04 |
| Cash per share | 0.36 |
| FCF per share | -0.17 |
| Tangible Book Value per share | -0.05 |
| Dividend per share | 0.00 |
Related companies: AVTX · CRBU · ENTA · EPRX · GNFT · IVVD · NAUT
Explore sector: Healthcare · Biotechnology
More sections of IVA: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks